StemCell Therapy

San Diego, CA/PRNewswire/ - ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that it has received a$10.1 millionStrategic Partnership Award from the California Institute for Regenerative Medicine (CIRM).

ViaCyte's innovative stem cell-based therapy for diabetes has been supported by several previous rounds of funding from CIRM, including a$20 millionDisease Team Award in 2009. This support has directly aided the development of VC-01, a regenerative medicine, combination product consisting of pancreatic beta cell progenitors encapsulated in a durable macroencapsulation device. When implanted under the skin of a patient with diabetes, VC-01 is expected to produce insulin and other factors which should safely and effectively control their disease. In its review of ViaCyte's application, CIRM's Grants Working Group characterized the Company's proposed therapy as the "holy grail" of diabetes treatments.

ViaCyte recently held a successful Pre-IND meeting with the United States Food and Drug Administration (FDA) and is on track to file an Investigational New Drug (IND) Application and initiate clinical evaluation of VC-01 in 2014. The Strategic Partnership Award from CIRM will be used to support these efforts, reflecting CIRM's commitment to following promising science through the progressive stages of product development.

"We are very grateful for the assistance that we are receiving from CIRM to advance our promising technology", stated Dr.Paul Laikind, President and CEO of ViaCyte. "Today's grant allows us to continue our efforts on behalf of theCaliforniataxpayers to break new ground with our stem cell-based product that has the potential to essentially cure patients with type 1 diabetes and provide a powerful new treatment for those with type 2 disease as well."

Approval of the award came from CIRM's governing board, the Independent Citizens Oversight Committee (ICOC), with advisement from the Scientific and Medical Research Funding Working Group. "ViaCyte has made good on their initial Disease Team award from CIRM, including a successful Pre-IND FDA meeting, and as a consequence, CIRM and the ICOC are glad to have the opportunity to continue funding ViaCyte's efforts to provide this product to patients with diabetes inCaliforniaand the rest of the world," said Dr.Alan Trounson, President of CIRM.

About ViaCyte

ViaCyte is a private company focused on developing a novel cell therapy for the treatment of diabetes. The Company's technology is based on the production of pancreatic beta cell progenitors derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered inSan Diego, Californiawith additional operations inAthens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

This news release may contain forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995.

About CIRM

Read the original post:
ViaCyte Receives $10.1M Strategic Partnership Award From CIRM To Continue Development Of Diabetes Therapy

This entry was posted on November 1, 2012 at 10:01 am and is filed under Regenerative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |